Oracea set to generate $260m sales in 2011

Written by on September 8, 2011 in Oracea (40mg doxycycline), patents with 0 Comments

An interesting note from the detailed interim judgement in the ongoing patent dispute between Galderma and Mylan.

As part of the proceedings Mylan looked at the on-going Oracea sales and projected that Galderma can expect to receive around $260 million in 2011.

MYLAN PHARMACEUTICALS INC., v.  GALDERMA LABORATORIES, L.P.; et. al.

Mylan projected that Oracea’s brand dollars for the period of January 2011  through December 2011  would be approximately $258.1  million.

Oracea’s sales growth was listed as

  • 2007: $43 million
  • 2008: $80.4 million
  • 2009: $155.3 million
  • 2010: $236.7 million
  • 2013: 319 million [updated]

Obviously a highly successful product for Galderma.

As I noted recently, the battle still has some way to go. As neither Galderma nor Mylan prevailed with all of their claims, further arguments are required from each party.

[update]: Oracea sales $319m y/e March 2013

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.